sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro.

CONCLUSIONS: sE-cadherin is overexpressed in serum of RCC patients and provides a functional cellular switch from sessility to aggressive dissemination. While sE-cadherin is not tumor-specific and thus inappropriate for population-based screening, further studies are warranted to investigate its role in monitoring RCC and employing it as a therapeutic target.
PMID: 31005422 [PubMed - as supplied by publisher]

Source: Urologic Oncology - April 17, 2019 Category: Urology & Nephrology Authors: Tsaur I, Hüsch T, Jüngel E, Schneider F, Schneider M, Haferkamp A, Thomas C, Lieb V, Wach S, Taubert H, Chun FK, Blaheta RA Tags: Urol Oncol Source Type: research